For a patient with metastatic NSCLC who had progression x2 at a single site treated w RT, would you switch systemic treatment?
Patient has been on pembrolizumab and had two symptomatic soft tissue mass treated with radiation.
1 Answer
Mednet Member
Medical Oncology · Florida Cancer Specialists & Research Institute
Answered on
Continue immunotherapy.
Join for free or sign in to see the full answer